Source-grounded facts extracted from Cryoport, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cryoport, Inc. reported first quarter (Q1) of 2026 results: revenue $47.8 million. Guidance raised.
“99.1) --- EX-99.1 2 tm2613494d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2026 Financial Results ● First quarter revenue grew 16% year-over-year to $47.8 million ● Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs ● Life Sciences Services”
Cryoport, Inc. completed a disposition involving designated affiliates of DHL Supply Chain International Holding B.V. for cash payments of approximately $200 million to Cryoport (closed 2025-06-11).
“specialty courier business, CRYOPDP, to DHL Group ( “ DHL ” ), one of the world ’ s leading logistics providers, in a transaction that includes cash payments of approximately $200 million to Cryoport. Concurrently, Cryoport and DHL have established a strategic partnership aimed at enhancing their respective supply chain service offerings for the global life”
Cryoport, Inc. reported the first quarter ended March 31, 2024 results: revenue $54.6 million, net income $0.43 per share, EPS $0.43 per share. Guidance reaffirmed.
“filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2413756d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results § Q1 2024 revenue of $54.6 million § 9% year-over-year increase in Commercial Cell & Gene Therapy revenue § 9% year-over-year increase in BioStorage/BioServices revenue § A total of 675 global clinical trials”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.